How much funding has Montai Therapeutics raised?

Montai Therapeutics has raised $50.0M in total funding, most recently a Series A round.

Who are Montai Therapeutics's investors?

Montai Therapeutics's investors include Flagship Pioneering.

When was Montai Therapeutics founded?

Montai Therapeutics was founded in 2019.

Where is Montai Therapeutics headquartered?

Montai Therapeutics is headquartered in Cambridge, United States.

What industry is Montai Therapeutics in?

Montai Therapeutics operates in Artificial Intelligence, Biotech.

Montai Therapeutics

Cambridge, United States · Founded 2019 · $50.0M raised

Artificial Intelligence

Biotech

Headquarters: Cambridge
Founded: 2019
Business Model: B2B
Website: montai.com

Total Funding: $50.0M
Last Round: $50.0M Series ADec 2022
Rounds: 1

About

Montai Therapeutics is harnessing AI to decode untapped, diverse chemistry to develop breakthrough oral medicines that address persistent unmet needs in chronic disease. With its CONECTA platform, Montai has built foundation models for decoding the complex language between nature's bioactive chemistry and human biology, supercharging drug discovery with new optionality and predictability. Founded in 2019 as a Flagship Pioneering company and led by co-founder and CEO Margo Georgiadis, Montai is advancing a pipeline of first-in-class oral medicines targeting validated biological pathways in inflammation and immunology, including biologic replacements and historically difficult-to-drug transcription factors.

Summary

Montai Therapeutics is an Artificial Intelligence company based in Cambridge, United States, founded in 2019. It has raised $50.0M in total across 1 round, most recently a $50.0M Series A round in Dec 2022. Investors include Flagship Pioneering.